XXXX.png
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
22 nov. 2024 16h30 HE | Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
XXXX.png
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
20 nov. 2024 08h30 HE | Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...
P1645378
KFSHRC Introduces Pioneering Virtual Pathology Services in Madinah KFSHRC Introduces Pioneering Virtual Pathology Services in Madinah
KFSH&RC Robotic Cardiac Surgery
KFSHRC to Host Minimally Invasive Organ Transplant Consensus Conference in Riyadh KFSHRC to Host Minimally Invasive Organ Transplant Consensus Conference in Riyadh
Hyku_Bio_ID_Primary_High.png
Hyku Biosciences Appoints John Gustofson to its Board of Directors
12 nov. 2024 07h45 HE | Hyku Biosciences
John Gustofson, MS, MBA appointed to the Board of Directors The appointment is in conjunction with Chugai Venture Fund joining syndicate with an investment that brings Hyku’s total seed financing to...
Nodenza Logo.png
Nodenza Venture Partners appoints George Freeman as Chair of Advisory Board
12 nov. 2024 07h00 HE | Nodenza Venture Partners
Nodenza Venture Partners appoints George Freeman as Chair of Advisory Board New York, November 12, 2024 – Nodenza Ventures Partners (“Nodenza”), today announces the appointment of George Freeman, MP,...
Logo_AdipoPharma_V1.png
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11 nov. 2024 12h43 HE | AdipoPharma
STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma, a biotech company headquartered in France with offices in the US and Belgium developing a novel and promising Type 2 diabetes drug,...
E'20-228_MAD_1952
KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment
Logo-OLON+payoff.jpg
Olon ist bereit für die Produktion in der neuen Anlage für hoch starke Wirkstoffe
04 nov. 2024 05h00 HE | Olon SpA
MAILAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Olon, ein Arzneimittelhersteller und globales CDMO-Unternehmen, bestätigt den Zeitplan für den Bau seiner neuen Produktionsanlage für hoch starke...
Logo-OLON+payoff.jpg
Olon is ready to host productions in the new facility dedicated to ultra-potent compounds
04 nov. 2024 05h00 HE | Olon SpA
Olon is ready to host productions in the new facility dedicated to ultra-potent compounds